NCT07130643View on ClinicalTrials.gov

Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

December 20, 2026

Study Completion Date

June 20, 2027

Conditions
HR+/HER2- Breast Cancer
Interventions
DRUG

CDK4/6 inhibitors+Endocrine Therapy

CDK4/6 inhibitors：dalpiciclib,palbociclib,abemaciclib,ribociclib

Trial Locations (1)

Unknown

No. 119 Zhuodaoquan South Road, Wuhan

All Listed Sponsors
lead

Xinhong Wu, PhD

OTHER

NCT07130643 - Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer | Biotech Hunter | Biotech Hunter